- Home
- PEPG vs BEAT Comparison
PEPG vs BEAT Comparison
Compare PEPG & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEPG
- BEAT
- Stock Information
- Founded
- PEPG 2018
- BEAT 2015
- Country
- PEPG United States
- BEAT United States
- Employees
- PEPG N/A
- BEAT N/A
- Industry
- PEPG Biotechnology: Pharmaceutical Preparations
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- PEPG Health Care
- BEAT Technology
- Exchange
- PEPG Nasdaq
- BEAT Nasdaq
- Market Cap
- PEPG 45.9M
- BEAT 37.7M
- IPO Year
- PEPG 2022
- BEAT 2021
- Fundamental
- Price
- PEPG $1.49
- BEAT $1.35
- Analyst Decision
- PEPG Buy
- BEAT Buy
- Analyst Count
- PEPG 3
- BEAT 1
- Target Price
- PEPG $7.67
- BEAT $8.00
- AVG Volume (30 Days)
- PEPG 335.1K
- BEAT 120.1K
- Earning Date
- PEPG 11-06-2025
- BEAT 11-06-2025
- Dividend Yield
- PEPG N/A
- BEAT N/A
- EPS Growth
- PEPG N/A
- BEAT N/A
- EPS
- PEPG N/A
- BEAT N/A
- Revenue
- PEPG N/A
- BEAT N/A
- Revenue This Year
- PEPG N/A
- BEAT N/A
- Revenue Next Year
- PEPG N/A
- BEAT N/A
- P/E Ratio
- PEPG N/A
- BEAT N/A
- Revenue Growth
- PEPG N/A
- BEAT N/A
- 52 Week Low
- PEPG $0.88
- BEAT $0.91
- 52 Week High
- PEPG $10.06
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- PEPG 64.86
- BEAT 58.04
- Support Level
- PEPG $1.13
- BEAT $1.34
- Resistance Level
- PEPG $1.32
- BEAT $1.54
- Average True Range (ATR)
- PEPG 0.09
- BEAT 0.11
- MACD
- PEPG 0.03
- BEAT 0.03
- Stochastic Oscillator
- PEPG 87.80
- BEAT 58.19
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.